The present study aimed to compare the cost-effectiveness of a CGM device (FreeStyle Libre 2) with a CBG device for managing glycemic control in inpatients with type 2 diabetes undergoing intensive insulin therapy. This evidence concerns the gene INS and type 2 diabetes mellitus.